Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/09/2010US20100310460 Compositions and methods for chelation therapy
12/09/2010US20100310458 Use of soluble ceacam8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis
12/09/2010DE202009018024U1 Quetiapin-Zusammensetzung Quetiapine composition
12/09/2010DE102009024296A1 New 1-(4-chloro-3-trifluoromethyl-phenyl)-3-(4-(pyridin-4-yloxy)-phen yl)-urea compounds useful to treat e.g. cancer, asthma, urticaria, arthritis, osteoarthritis, rheumatoid arthritis, sepsis, autoimmune diseases and multiple sclerosis
12/09/2010DE102009024133A1 Bacterial nanocellulose, useful e.g. for cartilage regeneration, comprises a structure consisting of a wide-meshed phase of bacterial nanocellulose and a close-meshed phase of bacterial nanocellulose firmly connected with wide-meshed phase
12/09/2010DE10200657B4 2:1-Komplex aus β- oder γ-Cyclodextrin und α-Tocopherol 2: 1 complex of β- or γ-cyclodextrin and α-tocopherol
12/09/2010CA2841499A1 Compositions and methods for preventing sternal wound infections
12/09/2010CA2801178A1 Nucleic acid delivery compositions and methods of use thereof
12/09/2010CA2764517A1 Dosage form
12/09/2010CA2764499A1 Interlaced method for treating cancer or a precancerous condition
12/09/2010CA2764473A1 Ophthalmic formulations of fluticasone and methods of use
12/09/2010CA2764465A1 Glomerulonephritis treatment
12/09/2010CA2764449A1 Nucleic acid modulators of glycoprotein vi
12/09/2010CA2764445A1 Polycyclic antagonists of lysophosphatidic acid receptors
12/09/2010CA2764387A1 Aminopyrrolidinone derivatives and uses thereof
12/09/2010CA2764374A1 Synthetic glucopyranosyl lipid adjuvants
12/09/2010CA2764339A1 Azole derivatives as wtn pathway inhibitors
12/09/2010CA2764331A1 Skin treatment compositions
12/09/2010CA2764327A1 Ophthalmic oil-in-water emulsions containing cyclosporine or a polyphenol
12/09/2010CA2764326A1 Therapeutic ophthalmic emulsions
12/09/2010CA2764296A1 Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides
12/09/2010CA2764249A1 17.beta.-alkyl-17.alpha.-oxy-oestratrienes
12/09/2010CA2764234A1 Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof
12/09/2010CA2764214A1 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
12/09/2010CA2764159A1 Active metabolite of a thrombin receptor antagonist
12/09/2010CA2764158A1 Polynucleotides for multivalent rna interference, compositions and methods of use thereof
12/09/2010CA2764051A1 Stabilised composition comprising at least one adrenergic compound
12/09/2010CA2764050A1 Stabilised composition comprising at least one adrenergic compound
12/09/2010CA2764043A1 Improved method for synthesizing pirfenidone
12/09/2010CA2764021A1 Gpr 119 modulators
12/09/2010CA2763962A1 Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide
12/09/2010CA2763893A1 Antagonism of human formyl peptide receptor for treatment of disease
12/09/2010CA2763822A1 Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof
12/09/2010CA2763821A1 1h-imidazo[4,5-c]quinolinone derivatives
12/09/2010CA2763819A1 Pure peg-lipid conjugates
12/09/2010CA2763529A1 Compositions and methods modulating mg29 for the treatment of diabetes
12/09/2010CA2763495A1 New compositions for treating cmt and related disorders
12/09/2010CA2763458A1 Topical micro-emulsions for the treatment of rheumatic disorders
12/09/2010CA2763266A1 Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians
12/09/2010CA2763040A1 Methods and compositions for the treatment of cancer
12/09/2010CA2762307A1 Crystalline forms of 6-(1h-imidazol-1-yl)-2-phenylquinazoline and salts thereof
12/09/2010CA2761227A1 Borinic compositions
12/09/2010CA2760825A1 Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
12/09/2010CA2760655A1 Heterocyclic compounds and expansion agents for hematopoietic stem cells
12/09/2010CA2760485A1 Borinic compositions
12/09/2010CA2758812A1 Method to stabilize a dietary supplement comprising glucosamine
12/09/2010CA2757083A1 Amino pyrimidine anticancer compounds
12/08/2010EP2258865A1 Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
12/08/2010EP2258848A1 Il-17 homologous polypeptide and therapeutic uses thereof
12/08/2010EP2258847A2 Futher novel forms of interfering RNA molecules
12/08/2010EP2258834A1 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
12/08/2010EP2258712A2 Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
12/08/2010EP2258711A2 New forms of 5-azacytidine
12/08/2010EP2258710A1 New polymorphic form of 5-azacytidine
12/08/2010EP2258708A1 Macrolide compounds endowed with antiinflammatory activity
12/08/2010EP2258705A1 Pharmaceutically acceptable salts of anti-infective quinolone compound
12/08/2010EP2258704A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
12/08/2010EP2258703A1 Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
12/08/2010EP2258702A2 Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors
12/08/2010EP2258701A1 2-morpholino-4-pyrimidone compound
12/08/2010EP2258700A1 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
12/08/2010EP2258699A1 Polymorphs of a pyrrole-substituted 2-Indolinone protein kinase inhibitor
12/08/2010EP2258698A2 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
12/08/2010EP2258697A1 Hydroxyquinoxalinecarboxamide derivative
12/08/2010EP2258694A1 Amines as histamine-3 receptor ligands and their therapeutic applications
12/08/2010EP2258689A1 Benzylated PDE4 inhibitors
12/08/2010EP2258688A1 Pyridinone derivatives for treatment of atherosclerosis
12/08/2010EP2258687A1 Nicotinamide derivates useful as P38 inhibitors
12/08/2010EP2258681A2 Aromatic Derivatives as HIV Aspartyl Protease Inhibitors
12/08/2010EP2258680A2 Aromatic derivatives as HIV aspartyl protease inhibitors
12/08/2010EP2258677A2 Histone deacetylase inhibitors and methods of use thereof
12/08/2010EP2258447A2 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
12/08/2010EP2258430A2 5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine
12/08/2010EP2258415A2 Medical devices containing rapamycin analogs
12/08/2010EP2258407A2 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
12/08/2010EP2258397A1 Polymer conjugate of physiologically active substance
12/08/2010EP2258396A1 Transdermally absorbable preparation
12/08/2010EP2258395A1 Therapeutic agent for fibroid lung
12/08/2010EP2258394A1 Oral dosage form comprising a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
12/08/2010EP2258393A1 Abc transporter protein expression inhibitor
12/08/2010EP2258383A2 Antigenic peptides derived from telomerase
12/08/2010EP2258379A1 Use of platelet rich plasma composition
12/08/2010EP2258378A1 Anti-tumor agent comprising cytidine derivative and carboplatin
12/08/2010EP2258377A2 Glycerophospholipids containing omega-3 and omega-6 fatty acids
12/08/2010EP2258376A1 Phosphonate analogs of HIV inhibitor compounds
12/08/2010EP2258375A1 17B-alkyl-17alpha-oxy-estratrienes
12/08/2010EP2258374A2 Use of maslinic acid for the treatment of diseases and the symptoms thereof by means of cox-2 inhibition
12/08/2010EP2258373A1 Composition comprising taurolidine and/or taurultam for the treatment of cancer
12/08/2010EP2258372A1 A2A antagonists for use in the treatment of motor disorders
12/08/2010EP2258371A1 Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
12/08/2010EP2258370A1 Treatment of malignant diseases
12/08/2010EP2258369A1 Medicated patch
12/08/2010EP2258368A2 Pharmaceutical compositions for nasal delivery
12/08/2010EP2258367A2 Use of palonosetron for treating post-operative nausea and vomiting
12/08/2010EP2258366A2 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
12/08/2010EP2258365A1 Use of organic compounds for immunopotentiation
12/08/2010EP2258364A1 Preventive and/or remedy for vascular diseases
12/08/2010EP2258363A1 Compositions for treatment of cancers
12/08/2010EP2258362A2 Titration dosing regimen for controlled release tramadol
12/08/2010EP2258361A1 Use of benzophenone derivative or salt thereof and tnf inhibitor in combination and pharmaceutical composition containing the derivative or salt thereof and the inhibitor
1 ... 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 ... 7860